StockData
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc. (ARCT) company profile

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value
$8.36−0.08 (-0.95%)

Close on Nov 13, 2026Market cap $237.62MP/E –Yield –

About Arcturus Therapeutics

Pharmaceutical Preparations, SIC 2834

Arcturus is a biotechnology company that develops messenger RNA medicines and vaccines targeting rare diseases and infectious conditions. The company utilizes proprietary lipid nanoparticle delivery and self-amplifying mRNA platforms to design its products. Its pipeline features KOSTAIVE, an approved self-amplifying mRNA vaccine for COVID-19, alongside therapeutic candidates in clinical evaluation for cystic fibrosis and ornithine transcarbamylase deficiency. Arcturus also advances vaccines against seasonal and pandemic influenza. The company collaborates with pharmaceutical partners, including CSL Seqirus and Meiji Seika Pharma, to commercialize vaccines, and targets patients with rare genetic respiratory and liver disorders.

Commercial distribution of the company's vaccine currently centers in Japan, with regulatory authorizations also established in the European Union and the United Kingdom. Its clinical development activities and clinical trials take place across several regions, including the United States, Europe, and Vietnam. The provided text does not mention the location of the company's headquarters.

Summary of the business section of Arcturus Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Arcturus Therapeutics Holdings Inc.
Headquarters
San Diego, CA
Address
10285 Science Center Drive
Phone
(858) 900-2660
Employees
111, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, San Diego, California

Stock & identifiers

Ticker
ARCT
Exchange
Nasdaq
IPO date
May 22, 2013
Shares outstanding
28M, Aug 4, 2026
Public float
$323.50M, Jun 30, 2025
Filer category
Accelerated filer<br>Smaller reporting company
Stock splits
1-for-7 reverse, Nov 16, 2017
SEC CIK
1768224
CUSIP
03969T109
ISIN
US03969T1097
FIGI
BBG00NNW8JK1
Share class FIGI
BBG00NNW8JL0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Joseph E. PaynePresident and CEO, Director1,480,097
Andy SassineChief Financial Officer, Director221,764
Dennis MulroyChief Financial Officer–
Pad ChivukulaChief Scientific Officer & COO435,334
Lance KurataChief Legal Officer–
Joseph RobertsController2,201
Jing L. MarantzDirector3,131
Magda MarquetDirector28,073
Peter C. FarrellDirector98,696
Moncef SlaouiDirector–
Edward W. HolmesDirector3,131
John MarkelsDirector3,131
James F. BarlowDirector13,131

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
Joseph E. Payne
President and Chief Executive Officer, Director
$750.00K$941.00K–$1.69M-54%
Dr. Padmanabh Chivukula
Chief Scientific Officer, Chief Operating Officer
$572.00K$290.00K–$862.00K-46%
Andy Sassine
Former Chief Financial Officer
$572.00K$37.50K$572.00K$1.18M-27%
Lance Kurata
Chief Legal Officer
$540.00K$290.00K–$830.00K-44%
Joe Roberts
Interim Principal Financial Officer and Accounting Officer; Controller
$219.58K$54.00K–$273.58K-33%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 111 employees, of which 106 were full-time and 5 were part-time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?